Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Immuneering Corp (IMRX)

91 + Investors. Track Smart Money conviction in IMRX. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +5
Streak
4Q ▲
Buyers last Q
56%

Smart Money Signals — IMRX

Based on 92 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 4 quarters in a row

last 6Q
For 4 consecutive quarters, more hedge funds added IMRX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
92 hedge funds hold IMRX right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +171% more funds vs a year ago

fund count last 6Q
+58 new funds entered over the past year (+171% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks. The peak was reached in just 4 quarters from the low — a sharp move.
🟡

Slight buying edge — 56% buying

57 buying44 selling
Last quarter: 57 funds bought or added vs 44 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
➡️

Steady new buyers — ~27 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 12 → 34 → 32 → 27. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
📌

Mixed — 30% long-term, 55% new

■ 30% conviction (2yr+) ■ 14% medium ■ 55% new
Of the 92 current holders: 28 (30%) held >2 years, 13 held 1–2 years, and 51 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.
💎

Buying through price weakness — shares -16%, value -33%

Value
-33%
Shares
-15%
Last quarter: funds added -16% more shares while total portfolio value only changed -33%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.
📈

Growing discovery — still being found

4 → 12 → 34 → 32 → 27 new funds/Q
New funds entering each quarter: 12 → 34 → 32 → 27. A growing number of institutions are discovering IMRX each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
🏛️

Veteran-anchored — 42% veterans vs 48% newcomers

■ 42% veterans ■ 10% 1-2yr ■ 48% new
Entry-cohort mix of 98 holders: 41 (42%) are 2+ year veterans, 10 entered 1–2 years ago, and 47 (48%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
🏆

Elite ownership — 58% AUM from top-100 funds

58% from top-100 AUM funds
30 of 92 holders are among the 100 largest funds by AUM, controlling 58% of total institutional value in IMRX. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
6.2
out of 10
Moderate Exit Risk
Exit risk score 6.2/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — IMRX

In 2026 Q1, 57 hedge funds were net buyers of IMRX (27 opened a new position, 30 added to an existing one), while 44 reduced or exited (22 trimmed, 22 sold completely) — a 56% buyer ratio, indicating a slight buying edge. This marks 4 consecutive quarters of net institutional buying — a persistent conviction signal. 58% of total institutional value in IMRX is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: +5 funds (more new holders than closures). Total institutional holders: 92.

Hedge Fund Ownership: IMRX

How many hedge funds hold IMRX — quarterly history vs. share price
Quarterly hedge fund ownership of IMRX vs. share price

Market Analysis: IMRX

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: IMRX

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Immuneering Corp (IMRX) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much IMRX has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 83d ago
IMRX
-16.3%
XLV
+705.0%

IMRX outperformed XLV by -721.3% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 38d ago
IMRX
-14.5%
XLV
+691.9%

Since the filing became public, IMRX outperformed XLV by -706.4% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

4 top-rated funds 1 high-conviction
Consensus
3.0
/ 10
breadth
×
Elite
1.2
/ 10
conviction
Hedge Fund Positioning: IMRX
91 + Investors

Track Smart Money conviction in IMRX. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 91 87 4.6%
13F Shares 27M 32M -16.34%
Total Value $132M $199M -33.69%
New Positions 26 32 -6
Increased Positions 29 27 +2
Closed Positions 22 14 +8
Reduced Positions 20 12 +8
Total Calls 3 4 -25.0%
Total Puts 3 3 -
PUT/CALL Ratio 1.0 0.75 Neutral

Statistics: IMRX

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

91 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in IMRX. Verified SEC 13F-HR filings.

QUARTER:
Top 25 IMRX holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Sanofi 4.25% 2,708,559 $14.3M
2 Occam Crest Management LP 1.74% 545,098 $2.9M
3 Pvg Asset Management Corp 0.36% 146,661 $615K
4 Diametric Capital, LP 0.24% 174,897 $922K
5 DCF Advisers, LLC 0.20% 141,462 $746K
6 Flower City Capital 0.15% 55,029 $290K
7 Prosight Management, LP 0.11% 123,409 $650K
8 Burkehill Global Management, LP 0.08% 300,000 $1.6M
9 Kelsey Financial, LLC 0.07% 15,099 $80K
10 Future Financial Wealth Managment LLC 0.07% 18,000 $104K
11 Alethea Capital Management, LLC 0.06% 22,935 $121K
12 683 Capital Management, LLC 0.04% 150,697 $794K
13 Thayer Partners, LLC / MA 0.03% 11,000 $54K
14 Summit Financial, LLC 0.03% 376,749 $2.0M
15 Palumbo Wealth Management LLC 0.02% 18,670 $98K
16 Landscape Capital Management, L.L.C. 0.02% 67,495 $356K
17 Berman McAleer LLC 0.02% 25,000 $132K
18 Tidemark, LLC 0.01% 10,000 $53K
19 Bridgeway Capital Management, LLC 0.01% 118,149 $623K
20 Prelude Capital Management, LLC 0.01% 29,219 $154K
21 Catalyst Funds Management Pty Ltd 0.01% 12,800 $67K
22 Marshall Wace, LLP 0.01% 1,996,585 $10.5M
23 Kingsview Wealth Management, LLC 0.01% 122,200 $644K
24 Weiss Asset Management LP 0.01% 87,985 $464K
25 Connor, Clark & Lunn Investment Management Ltd. 0.00% 400,363 $2.1M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Immuneering Corp (IMRX)

What does the Smart Money Trend signal show for IMRX?

Buying streak — 4 quarters in a row: For 4 consecutive quarters, more hedge funds added IMRX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for IMRX?

Slight buying edge — 56% buying: Last quarter: 57 funds bought or added vs 44 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for IMRX holders?

Elite ownership — 58% AUM from top-100 funds: 30 of 92 holders are among the 100 largest funds by AUM, controlling 58% of total institutional value in IMRX. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held IMRX?

Mixed — 30% long-term, 55% new: Of the 92 current holders: 28 (30%) held >2 years, 13 held 1–2 years, and 51 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Is it too late to buy Immuneering Corp (IMRX) following the 2026 Q1 hedge fund 13F filings?

As of today, IMRX has moved -14.5% since the 2026 Q1 13F filing date (May 15, 2026), compared to +691.9% for the XLV sector ETF — an outperformance of -706.4%. Since the quarter end (March 31, 2026), IMRX has gained -16.3% vs +705.0% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →